statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rezatapopt is a first-in-class precision oncology investigational therapy for patients with advanced solid tumors with a TP53 Y220C mutation and KRAS wild-type (WT)First patient dosed in Phase 2...

PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors

Phase 1 analysis from the PYNNACLE Phase 1/2 study showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated patients with advanced ovarian cancer harboring a TP53 Y220C mutation...

PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer

PEAK6 Investments LLC purchased a new position in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP  Free Report) during the third quarter, Holdings Channel.com reports. The fund purchased...

PEAK6 Investments LLC Invests $200,000 in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)

Connor Clark & Lunn Investment Management Ltd. increased its position in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP  Free Report) by 3.5% during the third quarter, according to the...

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares Purchased by Connor Clark & Lunn Investment Management Ltd.

PMV Pharmaceuticals reports FY results...

PMV Pharmaceuticals reports FY results

Strategic Focus on Rezatapopt Advances as Company Extends Cash RunwayRelated Stocks: PMVP...

PMV Pharmaceuticals Inc (PMVP) Reports Full Year 2023 Financial Results

Registrational, tumor-agnostic Phase 2 portion of PYNNACLE clinical trial of rezatapopt (PC14586), a first-in-class precision oncology investigational therapy in patients with advanced solid tumors...

PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights

PRINCETON, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...

PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference

Principal Financial Group Inc. lowered its position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP  Free Report) by 0.8% in the 3rd quarter, HoldingsChannel reports. The institutional investor...

Principal Financial Group Inc. Decreases Stock Position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)

Prioritization of PC14586 development and focused discovery research efforts results in a workforce reduction of approximately 30%Unaudited cash, cash equivalents, and marketable securities totaling...

PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway

PMV Pharmaceuticals, Inc. is a precision oncology company, which engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The company was founded by Arnold J. Levine, David Henry Mac, and Thomas E. Shenk in March 2013 and is headquartered in Princeton, NJ.

Volume	69,285.00
52-Wk High	$9.72
52-Wk Low	$1.18

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.36	--	--	N/A
Q4'23	-$0.34	-$0.30	11.76%	BEAT
Q3'23	-$0.46	-$0.34	26.54%	BEAT
Q2'23	-$0.49	-$0.38	21.76%	BEAT
Q1'23	-$0.46	-$0.42	8.13%	BEAT

PMVP PMV Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals